Adjuvant endocrine therapy, usually today with tamoxifen or an aromatase inhibitor (AI), is standard treatment for estrogen receptor-positive (ER+), early-stage breast cancer (BC), which accounts for approximately 75% of BC [1]. Here, CYP19A1 is linked to breast cancer.